What is the address of DR. JORIS HEYLIGEN, REUMATOLOGIE?

The registered office of DR. JORIS HEYLIGEN, REUMATOLOGIE is located at Litsebeek 40, 3740 Bilzen-Hoeselt.

Is DR. JORIS HEYLIGEN, REUMATOLOGIE still active?

Yes. According to the CBE (18 September 2026) DR. JORIS HEYLIGEN, REUMATOLOGIE is active, legal situation “Normale toestand”, started on 2 February 2023.

Is DR. JORIS HEYLIGEN, REUMATOLOGIE registered on Peppol?

Yes, DR. JORIS HEYLIGEN, REUMATOLOGIE is registered on the Peppol network with ID 0208:0797947536.

What is the enterprise number of DR. JORIS HEYLIGEN, REUMATOLOGIE?

The enterprise number of DR. JORIS HEYLIGEN, REUMATOLOGIE is BE0797947536.

When was DR. JORIS HEYLIGEN, REUMATOLOGIE founded?

DR. JORIS HEYLIGEN, REUMATOLOGIE was founded on 2 February 2023.

Who are the directors of DR. JORIS HEYLIGEN, REUMATOLOGIE?

According to the 2025 annual accounts, the directors of DR. JORIS HEYLIGEN, REUMATOLOGIE are: JORIS HEYLIGEN.

Is DR. JORIS HEYLIGEN, REUMATOLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 February 2023; 3 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. JORIS HEYLIGEN, REUMATOLOGIE make in 2025?

DR. JORIS HEYLIGEN, REUMATOLOGIE posted a profit after taxes of € 62,497 in financial year 2025.

What is the revenue of DR. JORIS HEYLIGEN, REUMATOLOGIE?

As a small company, DR. JORIS HEYLIGEN, REUMATOLOGIE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 87,719.

DR. JORIS HEYLIGEN, REUMATOLOGIE (Private Limited)

Dossier DR. JORIS HEYLIGEN, REUMATOLOGIE, printed on 18 September 2026 from databakkes.be/en/0797947536/dr-joris-heyligen-reumatologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. JORIS HEYLIGEN, REUMATOLOGIE from Bilzen-Hoeselt, company number BE0797947536, closed financial year 2025 with a result of € 62,497 after tax. For that financial year DR. JORIS HEYLIGEN, REUMATOLOGIE recorded a gross margin of € 87,719 and equity of € 149,874. Compared with financial year 2024, the result moved from € 49,723 to € 62,497. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 24, 2026.

What it is worth Growing

€ 149,874

▲ 72% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 62,497

▲ 26% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 135,172

▲ 83% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 144,874.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 21,322

▼ 30% vs 2024

Of which on lease € 20,007.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 15,818

▼ 39% vs 2024

€ 9,990 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 189

▼ 36% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 5,650

▼ 21% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 49,944 Gross margin 2023: € 49,944 First fiscal year in the series	€ 72,669 Gross margin 2024: € 72,669 ▲ 46% vs 2023 (€ 49,944) Favourable step	€ 87,719 Gross margin 2025: € 87,719 ▲ 21% vs 2024 (€ 72,669) Favourable step	▲ 21%
Profit after taxes	€ 32,655 Profit after taxes 2023: € 32,655 First fiscal year in the series	€ 49,723 Profit after taxes 2024: € 49,723 ▲ 52% vs 2023 (€ 32,655) Favourable step	€ 62,497 Profit after taxes 2025: € 62,497 ▲ 26% vs 2024 (€ 49,723) Favourable step	▲ 26%
Equity	€ 37,655 Equity 2023: € 37,655 First fiscal year in the series	€ 87,378 Equity 2024: € 87,378 ▲ 132% vs 2023 (€ 37,655) Favourable step	€ 149,874 Equity 2025: € 149,874 ▲ 72% vs 2024 (€ 87,378) Favourable step	▲ 72%
Total debts	€ 43,256 Total debts 2023: € 43,256 First fiscal year in the series	€ 35,632 Total debts 2024: € 35,632 ▼ 18% vs 2023 (€ 43,256) Favourable step	€ 22,987 Total debts 2025: € 22,987 ▼ 35% vs 2024 (€ 35,632) Favourable step	▼ 35%
Cash	€ 28,313 Cash 2023: € 28,313 First fiscal year in the series	€ 74,055 Cash 2024: € 74,055 ▲ 162% vs 2023 (€ 28,313) Favourable step	€ 135,172 Cash 2025: € 135,172 ▲ 83% vs 2024 (€ 74,055) Favourable step	▲ 83%
Retained profit	€ 32,655 Retained profit 2023: € 32,655 First fiscal year in the series	€ 82,378 Retained profit 2024: € 82,378 ▲ 152% vs 2023 (€ 32,655) Favourable step	€ 144,874 Retained profit 2025: € 144,874 ▲ 76% vs 2024 (€ 82,378) Favourable step	▲ 76%
Bank debt	€ 35,798 Bank debt 2023: € 35,798 First fiscal year in the series	€ 25,808 Bank debt 2024: € 25,808 ▼ 28% vs 2023 (€ 35,798) Favourable step	€ 15,818 Bank debt 2025: € 15,818 ▼ 39% vs 2024 (€ 25,808) Favourable step	▼ 39%
Balance sheet total	€ 80,911 Balance sheet total 2023: € 80,911 First fiscal year in the series	€ 123,010 Balance sheet total 2024: € 123,010 ▲ 52% vs 2023 (€ 80,911) Unchanged	€ 172,861 Balance sheet total 2025: € 172,861 ▲ 41% vs 2024 (€ 123,010) Unchanged	▲ 41%

Key figures of DR. JORIS HEYLIGEN, REUMATOLOGIE, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. JORIS HEYLIGEN, REUMATOLOGIE?

What happened at DR. JORIS HEYLIGEN, REUMATOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 24, 2026 New annual accounts for financial year 2025: profit of € 62,497 (▲ 26% vs 2024). Source: NBB ↗
Feb 2, 2023 New establishment in Bilzen-Hoeselt. KBO
2023 JORIS HEYLIGEN became a director. NBB
Feb 2, 2023 Start of the company according to the CBE. KBO

In short

From € 32,655 profit in 2023 to € 62,497 profit in 2025.

Paid € 37,016 in corporate taxes since 2023.

Best year ever: 2025, with € 62,497 profit.

Original PDFs at the National Bank ↗

A new publication or filing at DR. JORIS HEYLIGEN, REUMATOLOGIE? We notify you, reason included.

Follow DR. JORIS HEYLIGEN, REUMATOLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit